On February 10, 2021 Jiangsu Hengrui Medicine acquired China rights to a PI3kδ inhibitor (YY-20394) from Shanghai Yingli Pharma (Press release, Jiangsu Hengrui Medicine, FEB 10, 2021, View Source [SID1234575052]). Hengrui will make a $20 million investment in Yingli, and it will be responsible for clinical development of the candidate. PI3kδ inhibitors are expected to be effective treatments for hemotological tumors. Founded in 2011, Yingli Pharma is a small-molecule novel drug R&D company focused on treatments for hematological tumors, solid tumors and kidney-related metabolic diseases. It has an R&D center in Zhangjiang Park.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!